Evidence map›Paper›PMID 40005968›Full record

ReviewPharmaceuticals (Basel, Switzerland)2025

Potential Applications of Rare Earth Metal Nanoparticles in Biomedicine.

Svetlana A Titova, Maria P Kruglova, Victor A Stupin, Natalia E Manturova, Ekaterina V Silina

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Multifunctional rGO/YRSC advances · 2026
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Svetlana A TitovaI.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia.ORCID 0009-0009-8457-0222
Maria P KruglovaI.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia.ORCID 0000-0001-6939-160X
Victor A StupinPirogov Russian National Research Medical University, 117997 Moscow, Russia.ORCID 0000-0002-9522-8061
Natalia E ManturovaPirogov Russian National Research Medical University, 117997 Moscow, Russia.
Ekaterina V SilinaI.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia.ORCID 0000-0002-0246-5149

Funding

I.M. Sechenov First Moscow State Medical University (Sechenov University) development program project "Possibilities of bio-medical application of rare earth metal compounds"(grant manager Ekaterina V.) 04.000.y.128
6 · The paper itself

Abstract

In recent years, the world scientific community has shown increasing interest in rare earth metals in general and their nanoparticles in particular. Medicine and pharmaceuticals are no exception in this matter. In this review, we have considered the main opportunities and potential applications of rare earth metal (gadolinium, europium, ytterbium, holmium, lutetium, dysprosium, erbium, terbium, thulium, scandium, yttrium, lanthanum, europium, neodymium, promethium, samarium, praseodymium, cerium) nanoparticles in biomedicine, with data ranging from single reports of effects found in vitro to numerous independent in vivo studies, as well as a number of challenges to their potential for wider application. The main areas of application of rare earth metals, including in the future, are diagnosis and treatment of malignant neoplasms, therapy of infections, as well as the use of antioxidant and regenerative properties of a number of nanoparticles. These applications are determined both by the properties of rare earth metal nanoparticles themselves and the need to search for new approaches to solve a number of urgent biomedical and public health problems. Oxide forms of lanthanides are most often used in biomedicine due to their greatest biocompatibility and nanoscale size, providing penetration through biological membranes. However, the existing contradictory or insufficient data on acute and chronic toxicity of lanthanides still make their widespread use difficult. There are various modification methods (addition of excipients, creation of nanocomposites, and changing the morphology of particles) that can reduce these effects. At the same time, despite the use of some representatives of lanthanides in clinical practice, further studies to establish the full range of pharmacological and toxic effects, as well as the search for approaches to modify nanoparticles remain relevant.

Indexed as

antibacterial effectantioxidant effectantitumor effectcontrast agentslanthanidesnanoparticlesrare earth metalsrare earth oxidesregenerative effect

Identifiers

PMID40005968
PMCPMC11858778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.